Acumen pharmaceuticals reports second quarter 2025 financial results and business highlights

Newton, mass., aug. 12, 2025 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos) (“acumen” or the “company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (aΒos) for the treatment of alzheimer's disease (ad), today reported financial results for the second quarter of 2025 and provided a business update.
ABOS Ratings Summary
ABOS Quant Ranking